|Bid||0.00 x 900|
|Ask||0.00 x 1100|
|Day's Range||191.64 - 193.37|
|52 Week Range||114.27 - 202.22|
|Beta (5Y Monthly)||1.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 04, 2020 - Aug. 10, 2020|
|Forward Dividend & Yield||2.96 (1.53%)|
|Ex-Dividend Date||Apr. 15, 2020|
|1y Target Est||188.33|
FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.
On Allergan's (AGN) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
Allergan (AGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie's (ABBV) Q1 top line is likely to have been impacted by biosimilar competition for Humira in international markets. However, oncology drugs may have demonstrated strong growth.
DUBLIN , April 2, 2020 /CNW/ -- Allergan plc (AGN) today announced China's National Medical Products Administration (NMPA) approved the registration of Allergan's XEN® Gel Stent on March 26, 2020 for the surgical management of patients with refractory glaucoma. XEN® is the first product to be approved in China through the Real World Evidence pathway.
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.
Its economic impact now has investors doubting whether many companies who shook on mergers and acquisitions will see them completed. Traders and fund managers say the spread between agreed deal prices and subsequent trading in the stock of the acquisition targets is the widest they have come across. "I have been doing this for 25 years, and I have never seen panic like this coming out of merger arbitrage spreads," said Roy Behren, managing member of Westchester Capital Management, which has $4.1 billion in assets under management, most of it invested in merger arbitrage.
Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
AGN-151587 (EDIT-101) is the first in vivo CRISPR medicine to be administered to patients Additional patient enrollment to the BRILLIANCE Clinical Trial is ongoing DUBLIN,.
One of your companies gets a buyout offer and the shares soar. There might be different strategies for traders and investors on what to do next.